Opticon delays launch of clinical trial:
This article was originally published in Clinica
Executive Summary
Opticon Medical has delayed a pivotal clinical trial of its urinary catheter, the Option-vf, in order to implement an "engineering change" to a feature of the device, says the company. Opticon president William Post said that the delay in patient enrolment in exchange for the latest technology is "worth the trade off". Last year, the Dublin, Ohio-based company reported promising results from a pilot study of the Option-vf, which is designed for the short-term management of urinary retention following lower urinary tract surgery (see Clinica No 923, p 17).
You may also be interested in...
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.